```html

Insect‑Borne Encephalitis (Japanese Encephalitis)

Overview

Japanese encephalitis (JE) is a viral infection of the brain caused by the Japanese encephalitis virus (JEV), a flavivirus transmitted primarily by Culex mosquitoes that bite at dusk and night. Although the disease is named for Japan, it is endemic across large parts of Asia and the western Pacific, with more than 68,000 cases reported annually and an estimated 300,000–500,000 infections each year, most of which are asymptomatic.<sup>1,2</sup>

JE is a **zoonosis**—it circulates among birds (especially ardeid wading birds) and pigs, which serve as amplifying hosts. Humans are dead‑end hosts; once infected, they do not contribute to further spread.

Who it affects: Children and adolescents in endemic regions are most commonly affected because they have had fewer opportunities for natural immunity. Travelers to rural areas of endemic countries who are unvaccinated are also at risk.

Symptoms

Symptoms usually appear after an incubation period of 5–15 days. Approximately 1 in 25 infected persons develop clinical illness, and of those, about 20–30 % die or survive with permanent neurological deficits.

Early (Prodromal) Phase – 1–5 days

• Fever – often high‑grade, sudden onset.
• Headache – deep, throbbing.
• Fatigue / malaise – generalized weakness.
• Myalgia – muscle aches, especially in the neck and back.
• Nausea / vomiting – may be intermittent.

Neurologic Phase – 2–10 days after prodrome

• Altered mental status – confusion, agitation, or lethargy.
• Seizures – generalized or focal, may be the first sign of CNS involvement.
• Neck stiffness – sign of meningeal irritation.
• Photophobia – sensitivity to light.
• Focal neurologic deficits – weakness, paralysis, or loss of sensation in one limb or facial region.
• Movement disorders – tremor, ataxia (poor coordination).
• Coma – in severe cases.

Post‑acute / Recovery Phase

• Persistent cognitive impairment (memory loss, learning difficulties).
• Motor deficits (spasticity, paralysis).
• Speech and language problems.
• Behavioral changes (irritability, depression).

Causes and Risk Factors

Cause

JE is caused by the Japanese encephalitis virus, an RNA flavivirus closely related to West Nile and St. Louis encephalitis viruses. The virus circulates in an enzootic cycle involving:

• Vectors – Culex tritaeniorhynchus, Cx. vishnui, and other Culex species that breed in rice paddies and irrigated fields.
• Amplifying hosts – Domestic pigs and waterbirds (e.g., herons, egrets) harbor high viral loads, facilitating mosquito infection.
• Dead‑end hosts – Humans acquire infection through mosquito bites but do not develop sufficient viremia to infect new mosquitoes.

Risk Factors

• Living or traveling to rural or agricultural areas of endemic countries (India, China, Southeast Asia, parts of the Pacific).
• Spending evenings outdoors near rice fields, pig farms, or standing water.
• Age < 15 years in endemic regions (higher incidence due to lack of immunity).
• Unvaccinated travelers staying >1 month in endemic zones.
• Immunocompromised status (e.g., HIV, chemotherapy) – may increase risk of severe disease.

Diagnosis

Because early symptoms mimic many other febrile illnesses, a high index of suspicion is essential in endemic settings.

Clinical Assessment

• History of exposure (travel, outdoor activity, livestock contact).
• Neurologic examination for meningeal signs, seizures, focal deficits.

Laboratory Tests

• Serology – Detection of JEV‑specific IgM antibodies in serum or cerebrospinal fluid (CSF) using ELISA is the cornerstone. IgM appears 4–7 days after symptom onset.<sup>3</sup>
• RT‑PCR – Viral RNA can be identified in blood or CSF within the first week, but sensitivity declines rapidly.
• CSF analysis – Typically shows lymphocytic pleocytosis, elevated protein, normal glucose.
• Imaging
  • CT scan – May be normal or show cerebral edema.
  • MRI – Frequently demonstrates hyperintensities in the thalami, basal ganglia, midbrain, and spinal cord (T2/FLAIR).

Differential Diagnosis

Other arboviral encephalitides (e.g., West Nile, Dengue), bacterial meningitis, viral meningitis, and non‑infectious causes (e.g., autoimmune encephalitis) must be ruled out.

Treatment Options

There is no specific antiviral therapy for JEV; management is primarily supportive.

Hospital‑Based Care

• Fluid and electrolyte management – Prevent dehydration and maintain cerebral perfusion.
• Control of seizures – First‑line benzodiazepines (e.g., lorazepam) followed by anticonvulsants (e.g., levetiracetam, phenytoin).
• Reduction of intracranial pressure (ICP) – Elevate head of bed, osmotic agents (mannitol), or hyperventilation if needed.
• Respiratory support – Mechanical ventilation for patients with coma or impaired airway protection.
• Empiric antibiotics – Often started until bacterial meningitis is excluded.

Medications Under Investigation

Clinical trials have explored interferon‑α, ribavirin, and novel monoclonal antibodies, but none are currently FDA‑approved for JE.<sup>4</sup>

Lifestyle / Rehabilitation

• Early physiotherapy and occupational therapy to preserve motor function.
• Speech-language therapy for dysarthria or swallowing difficulties.
• Neuropsychological support for cognitive deficits.

Living with Insect‑Borne Encephalitis (Japanese Encephalitis)

Survivors often face long‑term neurologic sequelae. A multidisciplinary approach improves quality of life.

• Physical rehabilitation – Tailored exercise programs 3–5 times weekly; use assistive devices as needed.
• Cognitive rehabilitation – Memory games, structured routines, and occupational therapy.
• Psychological support – Counseling for depression, anxiety, or post‑traumatic stress.
• Medication management – Antispasticity agents (baclofen), anticonvulsants for epilepsy, analgesics for neuropathic pain.
• Regular follow‑up – Neurologist visits every 3–6 months during the first year, then annually.
• Community resources – Connect with local disability services, support groups, and government assistance programs.

Prevention

Prevention is the most effective strategy because treatment options are limited.

Vaccination

• Inactivated Vero cell vaccine (e.g., IXIARO®) – Two‑dose series administered 1 month apart, with a booster every 2–3 years for travelers at continued risk.
• Live‑attenuated SA 14‑14‑2 vaccine – Used widely in national immunization programs in China, India, and Nepal; single dose provides >90 % seroconversion.
• Vaccination is recommended for:
  • Residents of endemic rural areas, especially children 6 months–15 years.
  • Long‑term travelers (≥1 month) or short‑term travelers engaging in extensive outdoor activity.

Vector Control

• Eliminate standing water around homes; use larvicides in rice paddies where feasible.
• Install screens on windows and doors; keep doors closed at dusk.
• Apply EPA‑registered insect repellents containing DEET (≥30 %), picaridin, IR3535, or oil of lemon eucalyptus on exposed skin.
• Wear long‑sleeved shirts, long pants, and socks during evening hours.

Environmental Measures

• Separate pig pens from human dwellings; keep livestock areas well‑ventilated.
• Encourage community‑wide mosquito‑control programs (fogging, biological control with larvivorous fish).

Complications

Even with optimal supportive care, JE can lead to serious, sometimes permanent, complications.

• Neurologic sequelae – Cerebral palsy, spastic quadriplegia, persistent seizures, visual or auditory impairment.
• Psychiatric disorders – Depression, anxiety, personality changes.
• Secondary infections – Pneumonia or urinary tract infections in immobilized patients.
• Chronic pain – Neuropathic pain syndromes due to central nervous system injury.
• Mortality – Reported case‑fatality rates range from 20 % to 30 % among symptomatic patients.<sup>5</sup>

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Japanese encephalitis. https://www.mayoclinic.org/… (accessed May 2026).
2. World Health Organization. Japanese encephalitis fact sheet. https://www.who.int/… (2023).
3. Centers for Disease Control and Prevention. Japanese encephalitis - Diagnosis. https://www.cdc.gov/… (2022).
4. Gao L, et al. Antiviral therapies for Japanese encephalitis: a systematic review. J Infect Dis. 2021;223(9):1522‑1531.
5. Cleveland Clinic. Japanese encephalitis – Prognosis & outcomes. https://my.clevelandclinic.org/… (2024).

```